Sponsor Pipeline

Luminary Therapeutics Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
5
Active Trials
3
Recruiting
7
Disease Areas
What Changed in the Last 30 Days
First PostedNew Trial FilingPhaseStatus
2026-07-28 NCT07729995 BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease Phase 1 Not Yet Recruiting
Active Trials by Phase
Phase 1
5
Active Trials
NCT IDTitleConditionStatus
Phase 1
NCT05546723 LMY-920 for Treatment of Relapsed or Refractory Myeloma Multiple Myeloma, Refractory Recruiting
NCT05312801 Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma Lymphoma, Non-Hodgkin Lymphoma, B-Cell Recruiting
NCT06340750 BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus Systemic Lupus Erythematosus Recruiting
NCT07679919 BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies Non-Hodgkin Lymphoma Not Yet Recruiting
NCT07729995 BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease Rheumatoid Arthritis (RA) Not Yet Recruiting
Disease Areas
Non-Hodgkin Lymphoma (2) Multiple Myeloma (2) Lupus (SLE) (2) Leukemia (1) Chronic Lymphocytic Leukemia (CLL) (1) Rheumatoid Arthritis (1) Scleroderma (1)
Get alerts when Luminary Therapeutics's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free